By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name Aspen Technology, Inc.
Stock ticker AZPN
Live stock price [stckqut]AZPN[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Fair
Sales growth Good
EPS growth Good
P/E growth Poor
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $60.34
Target stock price (averages with growth) $57.32
Target stock price (averages with no growth) $25.79
Target stock price (manual assumptions) $50.37

The following company description is from Google Finance: http://www.google.com/finance?q=azpn

Aspen Technology, Inc. provides process optimization software solutions designed to manage and optimize plant and process design, operational performance and supply chain planning. The Company operates through two segments: subscription and software, and services. Its subscription and software segment is engaged in the licensing of process optimization software solutions and associated support services. The Company’s services segment includes professional services and training. Its aspenONE software and related services have been developed for companies in the process industries, including the energy, chemicals, and engineering and construction industries. The Company’s aspenONE software applications are organized into two suites: aspenONE Engineering, and aspenONE Manufacturing and Supply Chain. It has designed and developed its software applications across three principal business areas: Engineering, Manufacturing and Supply chain management.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Aspen Technology, Inc.

 

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Aspen Technology, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $39.09
  • Growth: 0.2
  • Current EPS (TTM): $1.63
  • P/E: 20
  • Future EPS Calc: $4.05
  • Future Stock Price Calc: $81.11
  • Target stock price: $50.36

[/s2If]
I hope that this makes you a Confident Investor.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments

Company name Alexion Pharmaceuticals, Inc.
Stock ticker ALXN
Live stock price [stckqut]ALXN[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $194.01
Target stock price (averages with growth) $214.38
Target stock price (averages with no growth) $97.29
Target stock price (manual assumptions) $189.11

The following company description is from Google Finance: http://www.google.com/finance?q=alxn

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Alexion Pharmaceuticals, Inc.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Alexion Pharmaceuticals, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $125.2
  • Growth: 0.2
  • Current EPS (TTM): $0.72
  • P/E: 170
  • Future EPS Calc: $1.79
  • Future Stock Price Calc: $304.57
  • Target stock price: $189.11

[/s2If]
I hope that this makes you a Confident Investor.